NLS Pharmaceutics AG

City:

Zurich

Country:

Switzerland

Published Applications:

Last publication date:

2025-08-28

Patent Grants:

Last grant date:

Top Inventors for applications by NLS Pharmaceutics AG

These are the the leading inventors for applications assigned to NLS Pharmaceutics AG:

Eric Konofal 4 Senlis, France
Emily Samuela TURILLI 1 Lecco, Italy

Recent patent applications by NLS Pharmaceutics AG

NLS Pharmaceutics AG based in Zurich, CH has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2025-08-28

US20250268859A1

Human necessities

OXAFURAMINE, (1R)-N-ETHYL-1-[(2R)-OXOLAN-2-YL]-2-PHENYLETHANAMINE, HYDROCHLORIDE AND DERIVATIVES THEREOF FOR TREATING ALZHEIMER'S DISEASE (AD), VASCULAR DEMENTIA, DEMENTIA WITH LEWY BODIES (DLB), MIXED DEMENTIA, FRONTOTEMPORAL LOBAR DEGENERATION (FTLD), AND PARKINSON'S DISEASE (PD)

#2 | 2025-03-13

US20250082598A1

Human necessities

Melafenoxate, 2-(1-adamantylamino)ethyl 2-(4-chlorophenoxy)acetate and derivatives thereof for treating circadian rhythm sleep disorders with neurodegenerative diseases such as Alzheimer's disease

#3 | 2025-02-13

US20250049737A1

Human necessities

Lauflumide and derivatives thereof for treating chronic fatigue syndrome and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

#4 | 2024-09-26

US20240316023A1

Human necessities

BENEDIN, PIPERIDINE, 2-BENZHYDRYL-3-HYDROXY-N-METHYL-, HYDROCHLORIDE AND DERIVATIVES THEREOF FOR USE IN TREATING KLEINE-LEVIN SYNDROME

Also check out NLS Pharmaceutics AG's (Zurich, Switzerland) applicant profile with 4 patent applications submitted.

AssigneeID:

625449 ⎘